cefotaxime and Hemorrhagic-Disorders

Various second- and third-generation cephem antibiotics were administered to infants 2 years of age or less. Excluding Streptococcus faecalis, which is resistant to cephems, all of the intestinal bacteria decreased in number, and in many cases these were replaced by yeasts. A positive reaction for protein induced by vitamin K absence or antagonism (PIVKA II) occurred in 25 to 63% of the subjects administered cephems possessing a methylthiotetrazole group, but not in those dosed with cefotaxime or ceftazidime. The effects of cefotaxime and latamoxef (moxalactam) on platelet ADP aggregation were also investigated. When these drugs were administered to clinical patients, moxalactam showed stronger inhibition of aggregation than cefotaxime.

Topics: Adenosine Diphosphate; Anti-Bacterial Agents; Bacteria; Cefotaxime; Child, Preschool; Female; Hemorrhagic Disorders; Humans; Infant; Infant, Newborn; Intestines; Male; Platelet Aggregation; Vitamin K Deficiency

Two new beta-lactam antibiotics, moxalactam and cefotaxime, were administered to two groups of patients with clinical indications for cephalosporin therapy and bacteriologically confirmed infection. The ten patients receiving moxalactam included five patients with impaired renal function; the ten receiving cefotaxime included seven with impaired renal function (serum creatinine greater than 1.3 mg/dl). Antibiotics were administered for seven days in dosages adjusted to the level of renal function. Serum trough levels, measured by microbiological assay, were within the therapeutic range: moxalactam median, 3 micrograms/ml (range, 0.6-20 micrograms/ml) and cefotaxime median, 2.9 micrograms/ml (range, 0.5-16 micrograms/ml).

Topics: Adolescent; Adult; Aged; Bleeding Time; Blood Coagulation Tests; Cefotaxime; Dose-Response Relationship, Drug; Hemorrhagic Disorders; Humans; Kidney Function Tests; Middle Aged; Moxalactam; Platelet Function Tests